Skip to content

Nasdaq · CIK 0001933414

MLYS Mineralys Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 10 d ago. Close $23.37 on Oct 9, 2026, +6% from the 52-week low and -51% from the high.

Last 90 days

Net insider value
-$5.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$5.2M by 4 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

MLYSOct 9, 2026 · close 23.37

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Mineralys Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
50ModerateJon Congleton
Chief Executive Officer
sell
$1.9M
75,000 shares
-12%+12% from low-47% from high
55ModerateBrian Taylor Slingsby
director
sell
$3.0M
104,320 shares
-1%+31% from low-38% from high
12WeakEric Warren
Chief Commercial Officer
sell
$209k
7,438 shares
-16%+26% from low-40% from high
14WeakDaphne Karydas
director
sell
$86k
3,000 shares
-33%-
55ModerateBrian Taylor Slingsby
director, owner
buy
$3.5M
259,259 shares
+3%+54% from low-10% from high
17WeakJon Congleton
Chief Executive Officer
sell
$187k
15,319 shares
-2%+53% from low-21% from high
58ModerateSrinivas Akkaraju
director
buy
$8.1M
600,000 shares
+12%+54% from low-10% from high
61NotableRa Capital Management, L.p.
director
buy
$17M
1,296,296 shares
+43%+54% from low-10% from high
16WeakJon Congleton
Chief Executive Officer
sell
$166k
18,333 shares
-2%-
0WeakDavid Malcom Rodman
Chief Medical Officer
sell
$75k
5,026 shares
-3%-
1WeakDavid Malcom Rodman
Chief Medical Officer
sell
$383k
25,482 shares
-16%-
25WeakJon Congleton
Chief Executive Officer
sell
$206k
15,271 shares
-2%-
21WeakAdam Scott Levy
CFO and Secretary
sell
$146k
10,757 shares
-4%-

Transactions

The last 40 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 30, 2026Jon Congleton
Chief Executive Officer
SOpen-market sale
Common Stock10b5-1
-75,000$25.46$1.9M528,62110 d ago
Sep 22, 2026Brian Taylor Slingsby
director
SOpen-market sale
Common Stockindirect: See footnote
-104,320$28.81$3.0M7,805,71818 d ago
Sep 21, 2026Eric Warren
Chief Commercial Officer
MOption exercise
Common Stock10b5-1
+7,438$13.24$98k45,83820 d ago
Sep 21, 2026Eric Warren
Chief Commercial Officer
SOpen-market sale
Common Stock10b5-1
-7,438$28.12$209k38,40020 d ago
Sep 21, 2026Eric Warren
Chief Commercial Officer
MOption exercise
Stock Optionderivative10b5-1
-7,438$0.00$0230,56320 d ago
Sep 15, 2026Daphne Karydas
director
MOption exercise
Common Stock10b5-1
+3,000$12.02$36k9,20025 d ago
Sep 15, 2026Daphne Karydas
director
SOpen-market sale
Common Stock10b5-1
-3,000$28.58$86k6,20025 d ago
Sep 15, 2026Daphne Karydas
director
MOption exercise
Stock Optionderivative10b5-1
-3,000$0.00$035,00025 d ago
Mar 13, 2025Brian Taylor Slingsby
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+259,259$13.50$3.5M8,903,838Apr 25, 2025
Apr 11, 2025Jon Congleton
Chief Executive Officer
SOpen-market sale
Common Stock10b5-1
-15,319$12.19$187k862,289Apr 15, 2025
Mar 13, 2025Srinivas Akkaraju
director
POpen-market purchase
Common Stockindirect: By Samsara BioCapital, L.P.
+600,000$13.50$8.1M5,674,916Mar 17, 2025
Mar 13, 2025Ra Capital Management, L.p.
director
POpen-market purchase
Common Stockindirect: See footnotes
+1,296,296$13.50$17M4,280,051Mar 17, 2025
Feb 13, 2025Ra Capital Management, L.p.
director
AGrant or award
Stock Option (Right to Buy)derivativeindirect: See Footnote
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Daphne Karydas
director
AGrant or award
Stock Optionderivative
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Alexander M Gold
director
AGrant or award
Stock Optionderivative
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Derek DiRocco
director
AGrant or award
Stock Optionderivative
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Brian Taylor Slingsby
director, owner
AGrant or award
Stock Optionderivative
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Srinivas Akkaraju
director, owner
AGrant or award
Stock Optionderivative
+32,900$0.00$032,900Feb 24, 2025
Feb 13, 2025Jon Congleton
Chief Executive Officer
AGrant or award
Stock Optionderivative
+570,000$0.00$0570,000Feb 24, 2025
Feb 13, 2025Brian Taylor Slingsby
director, owner
JOther
Stock Optionderivative
-32,900$0.00$00Feb 24, 2025
Feb 13, 2025Brian Taylor Slingsby
director, owner
JOther
Stock Optionderivativeindirect: See footnote
+32,900$0.00$032,900Feb 24, 2025
Jan 13, 2025Jon Congleton
Chief Executive Officer
SOpen-market sale
Common Stock10b5-1
-18,333$9.06$166k877,608Jan 15, 2025
May 22, 2024Brian Taylor Slingsby
director, owner
JOther
Stock Optionderivative
-22,000$0.00$00Jan 7, 2025
May 22, 2024Brian Taylor Slingsby
director, owner
JOther
Stock Optionderivativeindirect: See footnote
+22,000$0.00$022,000Jan 7, 2025
Dec 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock
+5,017$0.54$2,709146,008Dec 13, 2024
Dec 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative
-5,017$0.00$05,018Dec 13, 2024
Nov 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock10b5-1
+5,017$0.54$2,709140,991Nov 12, 2024
Nov 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock10b5-1
+5,026$1.08$5,428146,017Nov 12, 2024
Nov 11, 2024David Malcom Rodman
Chief Medical Officer
SOpen-market sale
Common Stock10b5-1
-5,026$15.00$75k140,991Nov 12, 2024
Nov 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative10b5-1
-5,017$0.00$010,035Nov 12, 2024
Nov 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative10b5-1
-5,026$0.00$0134,926Nov 12, 2024
Nov 6, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock10b5-1
+25,482$1.08$28k161,456Nov 8, 2024
Nov 6, 2024David Malcom Rodman
Chief Medical Officer
SOpen-market sale
Common Stock10b5-1
-25,482$15.03$383k135,974Nov 8, 2024
Nov 6, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative10b5-1
-25,482$0.00$0139,952Nov 8, 2024
Oct 11, 2024Jon Congleton
Chief Executive Officer
SOpen-market sale
Common Stock10b5-1
-15,271$13.52$206k895,941Oct 15, 2024
Oct 11, 2024Adam Scott Levy
CFO and Secretary
SOpen-market sale
Common Stock10b5-1
-10,757$13.57$146k236,854Oct 15, 2024
Oct 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock
+5,017$0.54$2,709130,622Oct 15, 2024
Oct 14, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Common Stock
+5,352$1.08$5,780135,974Oct 15, 2024
Oct 11, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative
-5,017$0.00$015,052Oct 15, 2024
Oct 14, 2024David Malcom Rodman
Chief Medical Officer
MOption exercise
Stock Optionderivative
-5,352$0.00$0165,434Oct 15, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

MLYS insider trading: Mineralys Therapeutics, Inc. | InsiderTell